Shares of Corcept Therapeutics (CORT) surged 5.61% in Wednesday's pre-market trading session, rebounding from a recent pullback as investors reacted to positive analyst sentiment and reassessed the company's valuation. The biotech firm, which has seen significant gains over the past year, is attracting attention due to its growth prospects and pipeline developments.

Truist Financial analyst Joon Lee reiterated a Buy rating on Corcept Therapeutics, signaling confidence in the company's future performance. This endorsement comes at a crucial time for the stock, which has experienced a -20.9% decline over the past month despite impressive gains of 31.1% over the last 12 months and 42.3% year-to-date.

The recent pullback may have created a potential buying opportunity for investors. While a discounted cash flow analysis suggests the stock might be overvalued, the company's price-to-earnings ratio of 56.8x is actually slightly below the calculated "Fair Ratio" of 62.3x, indicating that the current price could be reasonable given Corcept's growth profile and industry position. Analysts are projecting growth in free cash flow, with expectations of reaching $181.4 million by 2026, further supporting the positive outlook for the company.